Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara Gitlitz, Marianna Koczywas, Igor Espinoza-Delgado, David R Gandara

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

BACKGROUND: Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma. METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible. Belinostat was administered at 1000 mg/m intravenously over 30 minutes on days 1-5 of every 3 week cycle. The primary end point was response rate. The Simon two-stage design was used. Disease assessments were performed every two cycles. RESULTS: Thirteen patients were enrolled. Baseline characteristics were: median age of 73 years; Eastern Cooperative Oncology Group performance status 0 (n = 4), 1 (8) and 2 (1). A median of two cycles of therapy were administered. Disease stabilization was seen in two patients. No objective responses were noted and the study did not meet criteria to proceed to the second stage of accrual. Median survival was 5 months with a median progression-free survival of 1 month. Salient toxicities included nausea, emesis, fatigue, and constipation. One patient died as a consequence of cardiac arrhythmia which was deemed 'possibly' related to therapy. CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma. Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalJournal of Thoracic Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 2009
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Histone Deacetylases
Mesothelioma
Therapeutics
Constipation
Nausea
Disease-Free Survival
Vomiting
Fatigue
Cardiac Arrhythmias
Appointments and Schedules
Malignant Mesothelioma
belinostat
Drug Therapy
Survival

Keywords

  • Belinostat
  • Histone deacetylase inhibition
  • Mesothelioma
  • PXD 101

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. / Ramalingam, Suresh S.; Belani, Chandra P.; Ruel, Christopher; Frankel, Paul; Gitlitz, Barbara; Koczywas, Marianna; Espinoza-Delgado, Igor; Gandara, David R.

In: Journal of Thoracic Oncology, Vol. 4, No. 1, 01.2009, p. 97-101.

Research output: Contribution to journalArticle

Ramalingam, Suresh S. ; Belani, Chandra P. ; Ruel, Christopher ; Frankel, Paul ; Gitlitz, Barbara ; Koczywas, Marianna ; Espinoza-Delgado, Igor ; Gandara, David R. / Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 1. pp. 97-101.
@article{958e181efca741f9878a2526ee113dce,
title = "Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma",
abstract = "BACKGROUND: Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma. METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible. Belinostat was administered at 1000 mg/m intravenously over 30 minutes on days 1-5 of every 3 week cycle. The primary end point was response rate. The Simon two-stage design was used. Disease assessments were performed every two cycles. RESULTS: Thirteen patients were enrolled. Baseline characteristics were: median age of 73 years; Eastern Cooperative Oncology Group performance status 0 (n = 4), 1 (8) and 2 (1). A median of two cycles of therapy were administered. Disease stabilization was seen in two patients. No objective responses were noted and the study did not meet criteria to proceed to the second stage of accrual. Median survival was 5 months with a median progression-free survival of 1 month. Salient toxicities included nausea, emesis, fatigue, and constipation. One patient died as a consequence of cardiac arrhythmia which was deemed 'possibly' related to therapy. CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma. Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.",
keywords = "Belinostat, Histone deacetylase inhibition, Mesothelioma, PXD 101",
author = "Ramalingam, {Suresh S.} and Belani, {Chandra P.} and Christopher Ruel and Paul Frankel and Barbara Gitlitz and Marianna Koczywas and Igor Espinoza-Delgado and Gandara, {David R}",
year = "2009",
month = "1",
doi = "10.1097/JTO.0b013e318191520c",
language = "English (US)",
volume = "4",
pages = "97--101",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

TY - JOUR

T1 - Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

AU - Ramalingam, Suresh S.

AU - Belani, Chandra P.

AU - Ruel, Christopher

AU - Frankel, Paul

AU - Gitlitz, Barbara

AU - Koczywas, Marianna

AU - Espinoza-Delgado, Igor

AU - Gandara, David R

PY - 2009/1

Y1 - 2009/1

N2 - BACKGROUND: Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma. METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible. Belinostat was administered at 1000 mg/m intravenously over 30 minutes on days 1-5 of every 3 week cycle. The primary end point was response rate. The Simon two-stage design was used. Disease assessments were performed every two cycles. RESULTS: Thirteen patients were enrolled. Baseline characteristics were: median age of 73 years; Eastern Cooperative Oncology Group performance status 0 (n = 4), 1 (8) and 2 (1). A median of two cycles of therapy were administered. Disease stabilization was seen in two patients. No objective responses were noted and the study did not meet criteria to proceed to the second stage of accrual. Median survival was 5 months with a median progression-free survival of 1 month. Salient toxicities included nausea, emesis, fatigue, and constipation. One patient died as a consequence of cardiac arrhythmia which was deemed 'possibly' related to therapy. CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma. Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

AB - BACKGROUND: Belinostat (PXD 101) is a novel inhibitor of class I and II histone deacetylases. This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma. METHODS: Patients with advanced mesothelioma, progression with one prior chemotherapy regimen and Eastern Cooperative Oncology Group performance status 0-2 were eligible. Belinostat was administered at 1000 mg/m intravenously over 30 minutes on days 1-5 of every 3 week cycle. The primary end point was response rate. The Simon two-stage design was used. Disease assessments were performed every two cycles. RESULTS: Thirteen patients were enrolled. Baseline characteristics were: median age of 73 years; Eastern Cooperative Oncology Group performance status 0 (n = 4), 1 (8) and 2 (1). A median of two cycles of therapy were administered. Disease stabilization was seen in two patients. No objective responses were noted and the study did not meet criteria to proceed to the second stage of accrual. Median survival was 5 months with a median progression-free survival of 1 month. Salient toxicities included nausea, emesis, fatigue, and constipation. One patient died as a consequence of cardiac arrhythmia which was deemed 'possibly' related to therapy. CONCLUSIONS: Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma. Evaluation of combination strategies or alternate dosing schedules may be necessary for further development of this novel agent in mesothelioma.

KW - Belinostat

KW - Histone deacetylase inhibition

KW - Mesothelioma

KW - PXD 101

UR - http://www.scopus.com/inward/record.url?scp=61549123363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549123363&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318191520c

DO - 10.1097/JTO.0b013e318191520c

M3 - Article

C2 - 19096314

AN - SCOPUS:61549123363

VL - 4

SP - 97

EP - 101

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -